This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2018
  • /
  • 02
  • /
  • Phase III trial of DWP 450 meets primary endpoint ...
Drug news

Phase III trial of DWP 450 meets primary endpoint in glabellar lines study.- Evolus.

Read time: 1 mins
Last updated:18th Feb 2018
Published:18th Feb 2018
Source: Pharmawand

Evolus announced the presentation of data from the Phase III comparative clinical trial of its investigational DWP 450 (prabotulinumtoxinA) 900 kilodalton (kDa) neuromodulator . The study met the primary endpoint of non-inferiority at Day 30 with responder rates of 87.2% in the prabotulinumtoxinA group, 82.8% in the onabotulinumtoxinA group, and 4.2% in the placebo group. The adverse event assessed as study-drug related was 15.5%, 14.6% and 4.1% in the prabotulinumtoxinA, onabotulinumtoxinA and placebo groups, respectively. There were no serious adverse events that were assessed as study-drug related.

In the study, prabotulinumtoxinA and onabotulinumtoxinA, both 900 kDa botulinum toxin type A complexes, were studied in subjects with glabellar lines, also known as "frown lines" between the eyebrows. A total of 540 were enrolled: 245 received prabotulinumtoxinA; 246 received onabotulinumtoxinA; and 49 received placebo. The European and Canadian Phase III study, EVB-003, was presented at the American Academy of Dermatology (AAD) meeting.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.